Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

被引：13

作者：

Abou-Alfa, Ghassan K. ^{[1
,2
]}

Lau, George ^{[3
]}

Kudo, Masatoshi ^{[4
]}

Chan, Stephen L. ^{[5
]}

Kelley, Robin Kate ^{[6
]}

Furuse, Junji ^{[7
]}

Sukeepaisarnjaroen, Wattana ^{[8
]}

Kang, Yoon Koo ^{[9
]}

Dao, Tu Van ^{[10
]}

De Toni, Enrico N. ^{[11
]}

Rimassa, Lorenza ^{[12
,13
]}

Breder, Valeriy ^{[14
]}

Vasilyev, Alexander ^{[15
]}

Heurgue, Alexandra ^{[16
]}

Tam, Vincent C. ^{[17
]}

Mody, Kabir ^{[18
]}

Thungappa, Satheesh Chiradoni ^{[19
]}

Ostapenko, Yurii ^{[20
]}

Yau, Thomas ^{[21
]}

Azevedo, Sergio ^{[22
]}

Varela, Maria ^{[23
]}

Cheng, Ann-Lii ^{[24
,25
]}

Qin, Shukui ^{[26
]}

Galle, Peter R. ^{[27
]}

Ali, Sajid ^{[28
]}

Gupta, Charu ^{[29
]}

Makowsky, Mallory ^{[28
]}

Kurland, John F. ^{[28
]}

Negro, Alejandra ^{[28
]}

Sangro, Bruno ^{[30
,31
,32
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA

[2] Cornell Univ, Weill Med Coll, New York, NY USA

[3] Humanity & Hlth Med Grp, Humanity & Hlth Clin Trial Ctr, Hong Kong, Peoples R China

[4] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan

[5] Chinese Univ Hong Kong, Sir Yue Kong Pao Ctr Canc, Dept Clin Oncol, State Key Lab Translat Oncol, Hong Kong, Peoples R China

[6] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[7] Kanagawa Canc Ctr, Yokohama, Japan

[8] Khon Kaen Univ, Srinagarind Hosp, Dept Med, Khon Kaen, Thailand

[9] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[10] Natl Canc Hosp, Canc Res & Clin Trials Ctr, Dept Optimal Therapy, Hanoi, Vietnam

[11] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 2, Munich, Germany

[12] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[13] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Milan, Italy

[14] NN Blokhin Russian Canc Res Ctr, Chemotherapy Dept 17, Moscow, Russia

[15] Railway Clin Hosp, Dept Oncol, St Petersburg, Russia

[16] Robert Debre Hosp, Dept Hepatogastroenterol, Reims, France

[17] Univ Calgary, Tom Baker Canc Ctr, Dept Oncol, Calgary, AB, Canada

[18] Mayo Clin, Dept Med, Div Hematol Oncol, Jacksonville, FL USA

[19] Sri Venkateshwara Hosp, Bangalore, India

[20] Natl Canc Inst, Dept Minimally Invas & Endoscop Surg, Intervent Radiol, Kiev, Ukraine

[21] Queen Mary Hosp, Pok Fu Lam, Hong Kong, Peoples R China

[22] UPCO Hosp Clin Porto Alegre, Porto Alegre, Brazil

[23] Univ Oviedo, Hosp Univ Cent Asturias, Liver Unit, IUOPA,ISPA,FINBA, Oviedo, Spain

[24] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

[25] Natl Taiwan Univ Hosp, Taipei, Taiwan

[26] Nanjing Bayi Hosp, PLA Canc Ctr, Nanjing, Peoples R China

[27] Univ Med Ctr, Mainz, Germany

[28] AstraZeneca, Gaithersburg, MD USA

[29] AstraZeneca, Wilmington, DE USA

[30] Clin Univ Navarra, Liver Unit, Pamplona, Spain

[31] Clin Univ Navarra, HPB Oncol Area, Pamplona, Spain

[32] CIBEREHD, Pamplona, Spain

来源：

FUTURE ONCOLOGY | 2023年 / 19卷 / 38期

关键词：

clinical trial; durvalumab; hepatocellular carcinoma; immunotherapy; lay summary; liver cancer; plain language summary; Sorafenib; tremelimumab;

D O I：

10.2217/fon-2023-0486

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

What is this summary about?This is a summary of results from a phase 3 clinical study called HIMALAYA. HIMALAYA looked at treatment with one dose of a medication called tremelimumab combined with multiple doses of a medication called durvalumab (the STRIDE regimen) or multiple doses of durvalumab alone. These treatments were compared with a medication called sorafenib in participants with unresectable hepatocellular carcinoma (HCC).HCC is a type of liver cancer that is difficult to treat because it is often diagnosed when it is unresectable, meaning it can no longer be removed with surgery. Sorafenib has been the main treatment for unresectable HCC since 2007. However, people who take sorafenib may experience side effects that can reduce their quality of life, so alternative medicines are being trialed. Tremelimumab and durvalumab are types of drugs called immunotherapies, and they both work in different ways to help the body's immune system fight cancer.

引用

页码：2505 / 2516

页数：12